4D Molecular Therapeutics (NASDAQ:FDMT) Receives “Sell (E+)” Rating from Weiss Ratings

4D Molecular Therapeutics (NASDAQ:FDMT)‘s stock had its “sell (e+)” rating restated by analysts at Weiss Ratings in a report issued on Saturday,Weiss Ratings reports.

Other equities analysts have also issued research reports about the stock. Bank of America dropped their price target on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, March 10th. BMO Capital Markets lowered shares of 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $40.00 to $15.00 in a research report on Monday, January 13th. Morgan Stanley dropped their price target on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating for the company in a research report on Monday, January 13th. Chardan Capital dropped their price target on shares of 4D Molecular Therapeutics from $30.00 to $28.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th. Finally, Leerink Partners dropped their price objective on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating for the company in a research report on Monday, January 13th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, 4D Molecular Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $30.63.

4D Molecular Therapeutics Price Performance

NASDAQ:FDMT opened at $3.92 on Friday. 4D Molecular Therapeutics has a 1-year low of $3.58 and a 1-year high of $36.25. The firm has a 50 day simple moving average of $4.69 and a 200-day simple moving average of $7.39. The firm has a market cap of $181.50 million, a PE ratio of -1.38 and a beta of 2.83.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings results on Friday, February 28th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.10). As a group, sell-side analysts expect that 4D Molecular Therapeutics will post -2.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Decheng Capital LLC boosted its stake in shares of 4D Molecular Therapeutics by 0.5% in the fourth quarter. Decheng Capital LLC now owns 400,000 shares of the company’s stock valued at $2,228,000 after purchasing an additional 2,165 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of 4D Molecular Therapeutics by 7.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 44,324 shares of the company’s stock valued at $247,000 after purchasing an additional 2,925 shares during the period. PNC Financial Services Group Inc. boosted its stake in shares of 4D Molecular Therapeutics by 66.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company’s stock valued at $51,000 after purchasing an additional 3,630 shares during the period. Rhumbline Advisers boosted its stake in shares of 4D Molecular Therapeutics by 5.3% in the fourth quarter. Rhumbline Advisers now owns 73,431 shares of the company’s stock valued at $409,000 after purchasing an additional 3,675 shares during the period. Finally, ProShare Advisors LLC boosted its stake in shares of 4D Molecular Therapeutics by 30.1% in the fourth quarter. ProShare Advisors LLC now owns 16,369 shares of the company’s stock valued at $91,000 after purchasing an additional 3,783 shares during the period. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.